Functional Genomics and Genetics Shared Resource - Project Summary/Abstract The Functional Genomics and Genetics Shared Resource provides members of the CSHL Cancer Center with access to advanced RNAi and CRISPR screening technologies and services deriving genetically engineered cells and animals. This Shared Resource was recently established through reorganization and integration of services from the Microarray and RNA Quantitation Shared Resource, the Gene Targeting Shared Resource, and new technologies for shRNA and CRISPR screening. The recent revolution in sequencing technology has facilitated the collection of massive amounts of human genomic and expression data. To understand the human cancer genome and reveal therapeutic opportunities, a complementary set of functional genomics tools is required to systematically discover pathway relationships among genes. It is the goal of the Functional Genomics and Genetics Shared Resource to leverage its innovative approaches to RNAi and genome editing to promote discovery of new therapeutic targets and to create disease relevant models for improving human health. A major focus of this Shared Resource is in assisting investigators with the design, implementation, and data analysis of multi-plexed RNAi/CRISPR screens in mammalian cells. Functional genomic screening is primarily provided as a Shared Resource-assisted service with some full-service screening options. In addition, the Shared Resource also offers full-service construction of custom RNAi/CRISPR plasmid libraries. In order to extend functional assessment of genetic contributions in the context of genetically engineered cells and mice, this Shared Resource provides production of genetically modified mice using Cas9 and single guide RNA (sgRNA) microinjection into 1-cell mouse zygotes. A range of other gene targeting services, including gene targeting in mouse embryonic stem (ES) cells, derivation of ES cells from mouse models, production of chimeric mice by blastocyst injection, production of transgenic mice by pronuclear injection, cryopreservation/recovery of embryo and sperm, and in vitro fertilization are also available. Re-derivation of animals through this Shared Resource is also a key service for maintaining a pathogen-free animal facility. This Shared Resource will be vital to the Cancer Center because it will enable scientists to use genetic screening tools to discover novel cancer genes, therapeutic targets, and mechanisms of drug resistance and for developing new animal models of cancer for pre-clinical studies. Over the last grant period, 18 Cancer Center members (49% of the membership) used the combined services of the new Shared Resource.
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7: |
| Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67 |
| Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60 |
| Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804 |
| Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201 |
| Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605 |
| Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8: |
| Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361: |
| Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801 |
Showing the most recent 10 out of 380 publications
